Pfizer Health Services Research to Improve Management of mBC Patients Treated with Tucatinib
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Thursday 23rd, January 2025
External Deadline: Thursday 30th, January 2025
Description
Pfizer Global Medical Grants & Partnerships (GMGP) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMGP competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Date RFP Issued: November 11, 2024
Geographic Scope: Global
Clinical Area: HER2+ Metastatic Breast Cancer (mBC)
Link to full RFP: Health Services Research to Improve Management of mBC Patients Treated with Tucatinib
Application Due Date: January 30, 2025
Specific Area of Interest: Projects that will be considered for Pfizer support will be Investigator Sponsored/General Research proposals to improve therapy management of patients receiving tucatinib in combination with trastuzumab and capecitabine in clinical practice using innovative and community-accessible approaches that may impact patients adherence to treatment, quality of life, or symptom management, and/or facilitate follow-up in daily clinical practice.
Therapy management programs may include interventions including but not limited to:
- – Use of digital tools that may ease patients monitoring (i.e. Apps)
- – Education tools on safety profile and adverse events management such as infographics, training sessions, Patient Advocacy Group engagement.
– Multidisciplinary management: Primary Care Provider or General Practitioner engagement, oncology nurse consultations, call center, etc.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, (Nicola Fenderico) (Nicola.Fenderico@pfizer.com).